Free Trial

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's What Happened

Mineralys Therapeutics logo with Medical background
Remove Ads

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $14.30, but opened at $12.59. Mineralys Therapeutics shares last traded at $13.25, with a volume of 2,172,308 shares traded.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a report on Monday, March 10th. The Goldman Sachs Group dropped their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, Guggenheim reissued a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.

Get Our Latest Stock Analysis on MLYS

Mineralys Therapeutics Stock Performance

The stock's 50-day moving average is $10.42 and its 200 day moving average is $11.93. The stock has a market capitalization of $710.16 million, a PE ratio of -3.91 and a beta of 1.50.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. Analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Remove Ads

Insider Activity at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 18,333 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.06, for a total value of $166,096.98. Following the completion of the sale, the chief executive officer now owns 877,608 shares in the company, valued at $7,951,128.48. This represents a 2.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares of the company's stock, valued at approximately $2,057,482.70. This represents a 4.54 % decrease in their position. The disclosure for this sale can be found here. Insiders own 33.24% of the company's stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Mineralys Therapeutics during the 4th quarter worth approximately $48,000. ProShare Advisors LLC acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter worth $128,000. China Universal Asset Management Co. Ltd. grew its position in Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock valued at $130,000 after buying an additional 989 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Mineralys Therapeutics in the 4th quarter valued at $145,000. Finally, PDT Partners LLC acquired a new position in Mineralys Therapeutics in the 3rd quarter valued at $148,000. Institutional investors and hedge funds own 84.46% of the company's stock.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

Recommended Stories

Should You Invest $1,000 in Mineralys Therapeutics Right Now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads